Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC3402 + Azacitidine in MDS and CMML
NCT05970822Phase 1Recruiting
- Sponsor
- BioCity Biopharma
- Start
- Jun 2023
- Primary completion
- Mar 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BC3402 in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by BioCity Biopharma. Primary endpoints: Incidence of dose limiting toxicities (DLTs) at 28 days and Number of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs) at 2.5 years. Started Jun 2023; status: recruiting.
02
Drugs
BC3402
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05970822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970822.